These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 31756773)

  • 1. Genomic coamplification of CDK4/MDM2/FRS2 is associated with very poor prognosis and atypical clinical features in neuroblastoma patients.
    Amoroso L; Ognibene M; Morini M; Conte M; Di Cataldo A; Tondo A; D'Angelo P; Castellano A; Garaventa A; Lasorsa VA; Podestà M; Capasso M; Pezzolo A
    Genes Chromosomes Cancer; 2020 May; 59(5):277-285. PubMed ID: 31756773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consistent Amplification of FRS2 and MDM2 in Low-grade Osteosarcoma: A Genetic Study of 22 Cases With Clinicopathologic Analysis.
    He X; Pang Z; Zhang X; Lan T; Chen H; Chen M; Yang H; Huang J; Chen Y; Zhang Z; Jing W; Peng R; Zhang H
    Am J Surg Pathol; 2018 Sep; 42(9):1143-1155. PubMed ID: 30001240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment and characterization of a novel MDM2/MYCN-co-amplified neuroblastoma cell line, NBN-SHIM, established from a late recurrent stage MS tumor.
    Kato K; Nagai JI; Goto H; Shinkai M; Kitagawa N; Toyoda Y; Nishi T; Kigasawa H; Tanaka M; Kurosawa K; Ito Y; Haruta M; Kamijo T; Yoshimi A; Tsuchida M; Nagahara N; Tanaka Y
    Hum Cell; 2024 Sep; 37(5):1602-1609. PubMed ID: 39080217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amplification of FRS2 and activation of FGFR/FRS2 signaling pathway in high-grade liposarcoma.
    Zhang K; Chu K; Wu X; Gao H; Wang J; Yuan YC; Loera S; Ho K; Wang Y; Chow W; Un F; Chu P; Yen Y
    Cancer Res; 2013 Feb; 73(4):1298-307. PubMed ID: 23393200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GLI1 Coamplification in Well-Differentiated/Dedifferentiated Liposarcomas: Clinicopathologic and Molecular Analysis of 92 Cases.
    Sharma AE; Dickson M; Singer S; Hameed MR; Agaram NP
    Mod Pathol; 2024 Jun; 37(6):100494. PubMed ID: 38621503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-resolution genomic mapping reveals consistent amplification of the fibroblast growth factor receptor substrate 2 gene in well-differentiated and dedifferentiated liposarcoma.
    Wang X; Asmann YW; Erickson-Johnson MR; Oliveira JL; Zhang H; Moura RD; Lazar AJ; Lev D; Bill K; Lloyd RV; Yaszemski MJ; Maran A; Oliveira AM
    Genes Chromosomes Cancer; 2011 Nov; 50(11):849-58. PubMed ID: 21793095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the 12q15 MDM2 and 12q13-14 CDK4 amplicons and clinical correlations in osteosarcoma.
    Mejia-Guerrero S; Quejada M; Gokgoz N; Gill M; Parkes RK; Wunder JS; Andrulis IL
    Genes Chromosomes Cancer; 2010 Jun; 49(6):518-25. PubMed ID: 20196171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup.
    Martinez-Monleon A; Kryh Öberg H; Gaarder J; Berbegall AP; Javanmardi N; Djos A; Ussowicz M; Taschner-Mandl S; Ambros IM; Øra I; Sandstedt B; Beiske K; Ladenstein R; Noguera R; Ambros PF; Gordon Murkes L; Ljungman G; Kogner P; Fransson S; Martinsson T
    Sci Rep; 2022 Jul; 12(1):12420. PubMed ID: 35859155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone.
    Dujardin F; Binh MB; Bouvier C; Gomez-Brouchet A; Larousserie F; Muret Ad; Louis-Brennetot C; Aurias A; Coindre JM; Guillou L; Pedeutour F; Duval H; Collin C; de Pinieux G
    Mod Pathol; 2011 May; 24(5):624-37. PubMed ID: 21336260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics and outcome of patients with neuroblastoma presenting genomic amplification of loci other than MYCN.
    Guimier A; Ferrand S; Pierron G; Couturier J; Janoueix-Lerosey I; Combaret V; Mosseri V; Thebaud E; Gambart M; Plantaz D; Marabelle A; Coze C; Rialland X; Fasola S; Lapouble E; Fréneaux P; Peuchmaur M; Michon J; Delattre O; Schleiermacher G
    PLoS One; 2014; 9(7):e101990. PubMed ID: 25013904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MDM2 and CDK4 amplifications are rare events in salivary duct carcinomas.
    Grünewald I; Trautmann M; Busch A; Bauer L; Huss S; Schweinshaupt P; Vollbrecht C; Odenthal M; Quaas A; Büttner R; Meyer MF; Beutner D; Hüttenbrink KB; Wardelmann E; Stenner M; Hartmann W
    Oncotarget; 2016 Nov; 7(46):75261-75272. PubMed ID: 27662657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma.
    Chen QR; Bilke S; Wei JS; Whiteford CC; Cenacchi N; Krasnoselsky AL; Greer BT; Son CG; Westermann F; Berthold F; Schwab M; Catchpoole D; Khan J
    BMC Genomics; 2004 Sep; 5():70. PubMed ID: 15380028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A MYCN-amplified cell line derived from a long-term event-free survivor among our sixteen established neuroblastoma cell lines.
    Sugimoto T; Gotoh T; Yagyu S; Kuroda H; Iehara T; Hosoi H; Ohta S; Ohira M; Nakagawara A
    Cancer Lett; 2013 Apr; 331(1):115-21. PubMed ID: 23268333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of FRS2 in atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma: an immunohistochemical analysis of 182 cases with genetic data.
    Jing W; Lan T; Qiu Y; Peng R; Lu Y; Chen H; Chen M; He X; Chen C; Zhang H
    Diagn Pathol; 2021 Oct; 16(1):96. PubMed ID: 34696768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 12q amplification defines a subtype of extraskeletal osteosarcoma with good prognosis that is the soft tissue homologue of parosteal osteosarcoma.
    Kyriazoglou AI; Vieira J; Dimitriadis E; Arnogiannaki N; Teixeira MR; Pandis N
    Cancer Genet; 2012 Jun; 205(6):332-6. PubMed ID: 22749040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Refined mapping of 12q13-q15 amplicons in human malignant gliomas suggests CDK4/SAS and MDM2 as independent amplification targets.
    Reifenberger G; Ichimura K; Reifenberger J; Elkahloun AG; Meltzer PS; Collins VP
    Cancer Res; 1996 Nov; 56(22):5141-5. PubMed ID: 8912848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer.
    Simon R; Struckmann K; Schraml P; Wagner U; Forster T; Moch H; Fijan A; Bruderer J; Wilber K; Mihatsch MJ; Gasser T; Sauter G
    Oncogene; 2002 Apr; 21(16):2476-83. PubMed ID: 11971182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High amplification levels of MDM2 and CDK4 correlate with poor outcome in patients with dedifferentiated liposarcoma: A cytogenomic microarray analysis of 47 cases.
    Ricciotti RW; Baraff AJ; Jour G; Kyriss M; Wu Y; Liu Y; Li SC; Hoch B; Liu YJ
    Cancer Genet; 2017 Dec; 218-219():69-80. PubMed ID: 29153098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amplification of FRS2 in atypical lipomatous tumour/well-differentiated liposarcoma and de-differentiated liposarcoma: a clinicopathological and genetic study of 146 cases.
    Jing W; Lan T; Chen H; Zhang Z; Chen M; Peng R; He X; Zhang H
    Histopathology; 2018 Jun; 72(7):1145-1155. PubMed ID: 29368794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Tyrosine Kinase Adaptor Protein FRS2 Is Oncogenic and Amplified in High-Grade Serous Ovarian Cancer.
    Luo LY; Kim E; Cheung HW; Weir BA; Dunn GP; Shen RR; Hahn WC
    Mol Cancer Res; 2015 Mar; 13(3):502-9. PubMed ID: 25368431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.